CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-05 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −8,000 | $16.33 | $131K | 123,942 |
| 2024-07-01 | Michaelson Jennifer Chief Scientific Officer | Grant or award | +2,360 | $9.00 | $21K | 131,942 |
| 2024-06-26 | Webster Stephen W Director | Grant or award · Stock Option (Right to Buy) | +15,806 | 15,806 | ||
| 2024-06-26 | Rosenberg Anthony Director | Grant or award · Stock Option (Right to Buy) | +15,806 | 15,806 | ||
| 2024-06-26 | Martin Anne-Marie Director | Grant or award · Stock Option (Right to Buy) | +15,806 | 15,806 | ||
| 2024-06-26 | Ryan David P. Director | Grant or award · Stock Option (Right to Buy) | +15,806 | 15,806 | ||
| 2024-06-10 | Ebeling Thomas Director | Option exercise | +18,450 | $13.00 | $240K | 186,653 |
| 2024-06-10 | Ebeling Thomas Director | Option exercise · Stock Option (Right to Buy) | −18,450 | 0 | ||
| 2024-05-23 | Ebeling Thomas Director | Grant or award | +84,224 | $4.30 | $362K | 151,728 |
| 2024-05-23 | Ebeling Thomas Director | Grant or award | +16,475 | $12.73 | $210K | 168,203 |
| 2024-05-23 | Ebeling Thomas Director | Option exercise · Stock Option (Right to Buy) | −84,224 | 0 | ||
| 2024-05-23 | Ebeling Thomas Director | Option exercise · Stock Option (Right to Buy) | −16,475 | 0 | ||
| 2024-05-15 | Meek David D. Director | Grant or award · Stock Option (Right to Buy) | +15,618 | 15,618 | ||
| 2024-05-07 | Michaelson Jennifer Chief Scientific Officer | Option exercise 10b5-1 | +5,606 | $4.30 | $24K | 135,188 |
| 2024-05-07 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −5,606 | $30.06 | $169K | 129,582 |
| 2024-05-07 | Michaelson Jennifer Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,606 | 132,987 | ||
| 2024-05-06 | Michaelson Jennifer Chief Scientific Officer | Option exercise 10b5-1 | +50,000 | $4.30 | $215K | 187,582 |
| 2024-05-06 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −37,723 | $27.82 | $1.0M | 149,859 |
| 2024-05-06 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −20,277 | $28.54 | $579K | 129,582 |
| 2024-05-06 | Michaelson Jennifer Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 138,593 |
Page 6 of 23 · 446 trades